Singh Preeti, Augustine Dominic, Rao Roopa S, Patil Shankargouda, Awan Kamran Habib, Sowmya Samudrala Venkatesiah, Haragannavar Vanishri C, Prasad Kavitha
Departments of Oral Pathology and Microbiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India.
Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University, Jazan, Saudi Arabia.
J Carcinog. 2021 Sep 23;20:12. doi: 10.4103/jcar.JCar_14_20. eCollection 2021.
Targeting cancer stem cell (CSC) subpopulation within the tumor remains an obstacle for specific therapy in head-and-neck squamous cell carcinoma (HNSCC). Few studies in the literature describe a panel of stem cell makers, however a distinct panel has not been put forth. This systematic review aims to enhance the knowledge of additional markers to accurately relate their expression to tumorigenesis, metastasis, and therapy resistance. Databases, including and were searched from 2010 to 2017 using various combinations of the following keywords: "Stem cell markers in HNSCC" and "chemoresistance and radioresistence in HNSCC." Original experimental studies (both and ) published in English considering stem cell markers in HNSCC, were considered and included. We excluded articles on tumors other than HNSCC, reviews, editorial letters, book chapters, opinions, and abstracts from the analyses. Forty-two articles were included, in which 13 types of stem cell markers were identified. The most commonly expressed CSC markers were CD44, aldehyde dehydrogenase, and CD133, which were responsible for tumorigenesis, self-renewal, and therapy resistance, whereas NANOG, SOX-2, and OCT-4 were involved in metastasis and invasion. Identification of an accurate panel of CSC markers is the need of the hour as nonspecificity of the current markers poses a problem. Further studies with a large sample size would help validate the role of these CSC markers in HNSCC. These CSC proteins can be developed as therapeutic targets for HNSCC therapy, making future treatment modality more specific and effective.
针对头颈部鳞状细胞癌（HNSCC）肿瘤内的癌症干细胞（CSC）亚群仍然是特异性治疗的一个障碍。文献中很少有研究描述一组干细胞标志物，然而尚未提出一个明确的标志物组合。本系统评价旨在增进对其他标志物的了解，以准确地将它们的表达与肿瘤发生、转移和治疗抗性联系起来。从2010年到2017年，使用以下关键词的各种组合在包括 和 在内的数据库中进行搜索：“HNSCC中的干细胞标志物”和“HNSCC中的化学抗性和放射抗性”。考虑HNSCC中干细胞标志物的以英文发表的原始实验研究（包括 和 ）被纳入分析。我们排除了关于HNSCC以外肿瘤的文章、综述、编辑信件、书籍章节、观点以及分析中的摘要。纳入了42篇文章，其中鉴定出13种干细胞标志物类型。最常表达的CSC标志物是CD44、醛脱氢酶和CD133，它们负责肿瘤发生、自我更新和治疗抗性，而NANOG、SOX-2和OCT-4参与转移和侵袭。由于当前标志物的非特异性带来了问题，确定一组准确的CSC标志物是当务之急。进一步的大样本研究将有助于验证这些CSC标志物在HNSCC中的作用。这些CSC蛋白可被开发为HNSCC治疗的治疗靶点，使未来的治疗方式更具特异性和有效性。
